登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002653 证券简称：海思科 公告编号：2026-017 海思科医药集团股份有限公司 第五届董事会第三十六次会议 决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 表决结果：4票同意、0票弃权、0票反对 关联董事王俊民先生回避表决，公司独立董事对该事项进行了事前审议。 公司拟与海利克斯（成都）医药科技有限公司（以下简称"海利克斯"）共同投资9,700万元人民币设立 子公司海思生物科技有限责任公司（拟用名称，以工商登记为准，以下简称"海思生物"）,其中公司投 资8,700万元人民币，占海思生物股权比例89.69%，海利克斯投资1,000万元人民币，占海思生物股权比 例10.31%； 公司拟与海利克斯共同投资4,850万元人民币设立子公司海思新元医药科技有限责任公司（拟用名称， 以工商登记为准，以下简称"海思新元"）,其中公司投资4,350万元人民币，占海思新元股权比例 89.69%，海利克斯投资500万元人民币，占海思新元股权比例10.31%。 详见同日刊登在巨潮资讯网等公司指定信息披露媒体的 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 公司于2025年4月30日披露了《吉林华微电子股份有限公司关于公司股票被实施退市风险警示并被继续 实施其他风险警示暨停牌的公告》（公告编号：2025-036），因公司2024年度的财务会计报告被出具无 法表示意见的审计报告，根据《上海证券交易所股票上市规则》第9.3.2条第一款第(三)项的规定，出 现"最近一个会计年度的财务会计报告被出具无法表示意见或否定意见的审计报告"的情形，公司股票于 2025年5月6日起被实施退市风险警示并被继续实施其他风险警示。 若公司2025年度仍然存在《上海证券交易所股票上市规则》第9.3.7条规定的不符合申请撤销股票交易退 市风险警示的情形，或者未在规定期限内申请撤销退市风险警示的，公司股票将面临被终止上市的风 险。 二、历次终止上市风险提示公告的披露情况 根据《上海证券交易所股票上市规则》第9.3.6条规定"上市公司股票因第9.3.2条第一款第（一）项至第 （三）项规定情形被实施退市风险警示的，公司应当在其股票被实施退市风险警示当年的会计年度结束 后1个月内，披露股票可能被终止上市的风险提示公告，并在首次风险提示公告披露后至年 ...

Core Viewpoint - The company has approved an employee stock ownership plan (ESOP) aimed at enhancing employee engagement and aligning their interests with shareholders through stock ownership [1][2]. Group 1: Employee Stock Ownership Plan Approval - The company held a board meeting on December 12, 2024, and a shareholder meeting on December 30, 2024, to approve the ESOP and related management measures [1]. - The board authorized the management to handle matters related to the ESOP implementation [1]. Group 2: Stock Buyback Details - The company plans to repurchase between 7 million and 13.5 million shares of its A-shares, with a maximum buyback price of 9.80 yuan per share, totaling up to 132.3 million yuan [2]. - The actual buyback completed was 10,396,000 shares, costing approximately 69.99 million yuan [2]. Group 3: Fundraising and Subscription Details - The ESOP aims to raise a total of up to 46.68 million yuan, with a subscription price of 4.49 yuan per share, allowing for the purchase of up to 10.396 million shares [4]. - The actual funds raised amounted to 31.74 million yuan, with 29 employees participating in the subscription [4]. Group 4: Share Transfer and Accounting - As of February 12, 2026, 7,070,000 shares were transferred to the ESOP account, representing 1.393% of the company's total share capital [5]. - The company will follow accounting standards for share-based payments to assess the impact of the ESOP on its financial results [7]. Group 5: Independence and Governance - The first major shareholder did not participate in the ESOP, ensuring no conflict of interest [6]. - The ESOP holders are independent from the company's major shareholders and management, with a governance structure that prevents any single holder from exerting significant influence [6].

Group 1 - The company received a notification from its controlling shareholder, Cheng Xianfeng, regarding the extension of the pledge on a portion of his shares on February 12, 2026 [1] - The announcement includes details about the basic situation of the shareholder's share pledge extension [1] - As of the date of the announcement, the cumulative pledge situation of shares held by Cheng Xianfeng and his concerted actors is disclosed [1] Group 2 - The company has provided documentation related to the pledge extension [1] - The board of directors of the company issued this announcement on February 13, 2026 [2]

浙江京新药业股份有限公司（以下简称"公司"）已于2026年2月11日向香港联合交易所有限公司（以下 简称"香港联交所"）递交了发行境外上市股份（H股）并在香港联交所主板挂牌上市（以下简称"本次 发行并上市"）的申请，并于同日在香港联交所网站刊登了本次发行并上市的申请资料。该申请资料为 公司按照香港证券及期货事务监察委员会（以下简称"香港证监会"）及香港联交所的要求编制和刊发， 为草拟版本，其所载资料可能会适时作出更新及修订，投资者不应根据其中的资料作出任何投资决定。 鉴于本次发行并上市的认购对象仅限于符合相关条件的境外投资者及依据中国相关法律法规有权进行境 外证券投资的境内合格投资者，公司将不会在境内证券交易所的网站和符合境内监管机构规定条件的媒 体上刊登该申请资料，但为使境内投资者及时了解该等申请资料披露的本次发行并上市以及公司的其他 相关信息，现提供该申请资料在香港联交所网站的查询链接供查阅： 中文： 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗漏。 浙江京新药业股份有限公司 董事会 2026年2月12日 http ...

登录新浪财经APP 搜索【信披】查看更多考评等级 敬请广大投资者详细了解可转换公司债券（以下简称"可转债"）相关规定，并及时关注公司后续公告， 注意投资风险。 一、可转债基本情况 （一）可转债发行情况 经中国证券监督管理委员会《关于同意北京浩瀚深度信息技术股份有限公司向不特定对象发行可转换公 司债券注册的批复》（证监许可〔2025〕71号）同意注册，北京浩瀚深度信息技术股份有限公司（以下 简称"公司"）向不特定对象发行了354.29万张可转换公司债券，每张面值为人民币100元，发行总额为 35,429.00万元，扣除承销及保荐费用等与发行有关的费用864.84万元后，募集资金净额为34,564.16万 元。上述募集资金已全部到位，2025年3月20日由中兴财光华会计师事务所（特殊普通合伙）进行审验 并出具了《验资报告》（中兴财光华审专字（2025）第102009号）。 （二）可转债上市情况 经上海证券交易所自律监管决定书〔2025〕70号文同意，公司35,429.00万元可转换公司债券于2025年4 月7日起在上海证券交易所交易，债券简称"浩瀚转债"，债券代码"118052"。 本公司董事会及全体董事保证本公 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688183 证券简称：生益电子 公告编号：2026-007 生益电子股份有限公司董事会 2026年2月13日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 生益电子股份有限公司（以下简称"公司"）于2026年2月11日收到上海证券交易所出具的《关于受理生 益电子股份有限公司科创板上市公司发行证券申请的通知》（上证科审（再融资）[2026]20号）。上海 证券交易所依据相关规定对公司报送的科创板上市公司发行证券的募集说明书及相关申请文件进行了核 对，认为该项申请文件齐备，符合法定形式，决定予以受理并依法进行审核。 公司本次向特定对象发行A股股票事项尚需通过上海证券交易所审核，并获得中国证券监督管理委员会 （以下简称"中国证监会"）作出予以注册的决定后方可实施。上述事项最终能否通过上海证券交易所审 核，并获得中国证监会予以注册的决定及其时间尚存在不确定性。公司将根据该事项的进展情况及时履 行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 生益电子股份有限公 ...

特别提示 持有大族激光科技产业集团股份有限公司（本公告中简称"公司"或"大族激光"）股份161,773,306股（占 公司总股本比例15.71%）的控股股东大族控股集团有限公司（本公告中简称"大族控股"）计划在本公告 披露之日起15个交易日后的3个月内以集中竞价方式减持公司股份不超过9,958,170股（占公司总股本 1,029,603,408股的比例0.9672%）。 公司近日接获控股股东大族控股出具的《股份减持计划告知函》，现将具体情况公告如下： 一、股东的基本情况 截至本公告披露日，大族控股系公司控股股东，持有公司股份161,773,306股，占公司总股本比例 15.71%；大族控股的一致行动人高云峰先生持有公司股份96,319,535股，占公司总股本比例9.36%。大 族控股及其一致行动人高云峰先生合计持有公司股份258,092,841股，占公司总股本比例为25.07%。 登录新浪财经APP 搜索【信披】查看更多考评等级 控股股东大族控股集团有限公司保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 7 ...

Core Viewpoint - The announcement details the convening of a communication-based meeting for the fund holders of the China Europe Fund Management Co., Ltd. regarding the ongoing operation of the China Europe CSI A50 Index Securities Investment Fund, necessitated by the fund's asset value falling below 50 million yuan for 60 consecutive working days [20][21]. Meeting Basic Information - The fund management company has decided to hold the meeting via communication methods, with voting starting from March 2, 2026, to March 16, 2026, at 17:00 [2][5]. - The counting date for the votes is set for March 17, 2026 [3]. Meeting Agenda - The main agenda item for the meeting is the proposal regarding the continuous operation of the China Europe CSI A50 Index Securities Investment Fund [4]. Voting Process - Fund holders can submit their votes through a designated voting ticket, which can be downloaded from the fund management company's website or the China Securities Regulatory Commission's electronic disclosure website [6][22]. - Specific requirements for individual and institutional investors regarding the submission of voting tickets and necessary documentation are outlined [7][8]. Voting Validity and Conditions - Valid votes must be submitted within the specified voting period and meet the documentation requirements [12]. - The resolution will be effective if more than half of the voting rights are represented by valid votes from fund holders [14]. Second Meeting Notice - If the initial meeting does not meet the required quorum, a second meeting will be scheduled, with the same registration date of February 26, 2026, remaining applicable [15][16]. Related Institutions - The meeting is organized by China Europe Fund Management Co., Ltd., with supervision by Ningbo Bank Co., Ltd. and notarization by Shanghai Dongfang Notary Office [17].

Group 1 - The company held its ninth board meeting on February 11, 2026, where all nine directors were present, and the meeting was conducted in accordance with legal requirements [1][2][3] - The board approved the establishment of a technology joint research center with Tsinghua University, with an investment of 50 million yuan, which is not expected to have a significant short-term impact on the company's performance [2] - The board also approved the proposal for the company to conduct commodity futures hedging business for the year 2026, which will be submitted for shareholder approval [4][9] Group 2 - The purpose of the hedging business is to mitigate risks associated with price fluctuations of raw materials such as copper, zinc, aluminum, nickel, and lead, which are essential for the company's production [10] - The company plans to invest up to 3 billion yuan in the hedging business using its own funds, with the investment period lasting for 12 months from the date of shareholder approval [11][13] - The hedging activities will be limited to raw materials directly related to the company's operations, and the company will implement strict internal controls and risk management measures [12][18] Group 3 - A second extraordinary general meeting of shareholders is scheduled for March 3, 2026, to discuss the approved proposals from the board meeting [6][20] - The meeting will allow for both on-site and online voting, with specific timeframes for participation [23][24] - Shareholders must register to attend the meeting, and detailed procedures for voting and registration have been outlined [30][31]